| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Feb 2026 | 22 Jan 2026 |
| Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve Un-audited Financial Results for the third quarter and nine months ended December 31, 2025. Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine months ended on 31 December 2025 (As Per BSE Announcement Dated on : 05.02.2026) | ||
| Board Meeting | 6 Nov 2025 | 24 Oct 2025 |
| Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30 September 2025. Unaudited Financial Results (Standalone and Consolidated) for the quarter and Half Year ended on 30 September 2025 Please refer attached intimation. (As Per BSE Announcement Dated on 06.11.2025) | ||
| Board Meeting | 7 Aug 2025 | 21 Jul 2025 |
| Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30 June 2025 Considered and Approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on 30 June 2025 (As Per BSE Announcement Dated on: 07.08.2025) Reappointment of Mr. Krishnamraju Kanumuri as Managing Director and CEO of the Company. (As Per BSE Announcement Dated on 08.08.2025) | ||
| Board Meeting | 9 Jun 2025 | 9 Jun 2025 |
| Allotment of Equity Shares on conversion of ESOPs. | ||
| Board Meeting | 13 May 2025 | 6 May 2025 |
| Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 inter alia to consider and approve The meeting of Board of Directors will be held on 13 May 2025 to consider and approve the Audited Financial results for the Quarter and Year ended 31st March 2025 Considered and Approved the Audited Financial Results for the Financial Year ended 31st March, 2025. (As Per BSE Announcement dated on 13.05.2025) As per the letter attached Allotment of securities as per attachment (As Per BSE Announcement dated on 14.05.2025) | ||
| Board Meeting | 24 Mar 2025 | 24 Mar 2025 |
| Appointment of Dr. Dinesh V Patel (DIN: 11010657) as Additional Director of the Company under the category of Independent Director With reference to the Intimation for Allotment dated 24.03.2025. Please find the attached revised Intimation for allotment on conversion of ESOPs into Equity. | ||
The estimated sale value of these shares is about ₹2,500 Crore. As per reports, the transaction shall take place at a floor price of ₹860 per share.
Here are some of the stocks that may see significant price movement today: IREDA, Tata Motors, Sai Life Sciences, etc.
The IPO that was opened between December 11 and December 13, 2024 aggregates to ₹3,042.62 crore and has had a price band of ₹533-549 per equity share.
Investors can bid for up to 27 shares in a single lot, with the company setting a price range of Rs 522-549 per share.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
